High-density lipoprotein: Antioxidant and anti-inflammatory properties

Navab, Mohamad; Yu, Roger; Gharavi, Nima M.; Huang, William; Ezra, Navid; Lotfizadeh, Ali; Anantharamaiah, G.M.; Alipour, Nima; Lenten, Brian J. Van; Reddy, Srinivasa T.; Marelli, Daniel

doi:10.1007/s11883-007-0026-3

Cited by 86 publications

(56 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the current study, UFPs reduced HDL anti-oxidant capacity as measured by its ability to inhibit LDL oxidation. HDL anti-atherogenic properties include the abilities to exert anti-oxidant and anti-infl ammatory actions in the vasculature ( 8,9 ). The data from the current study are in agreement with the report revealing the anti-oxidant capacity of HDL is signifi cantly impaired in patients with acute coronary syndromes as compared with healthy individuals or those with stable coronary artery disease ( 32 ).…”

Section: Discussionsupporting

confidence: 91%

Ambient ultrafine particles alter lipid metabolism and HDL anti-oxidant capacity in LDLR-null mice

Navab

Pakbin

et al. 2013

Journal of Lipid Research

Self Cite

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 91%

Ambient ultrafine particles alter lipid metabolism and HDL anti-oxidant capacity in LDLR-null mice

Navab

Pakbin

et al. 2013

Journal of Lipid Research

Self Cite

View full text Add to dashboard Cite

“…39,40 This study also found an association between CRP and HDL-C. This finding is particularly important because high density lipoprotein cholesterol has both antioxidant and anti-inflammatory effects, 41 hence patients with low HDL-C may have higher degree of inflammation and oxidative stress.…”

Section: Discussionmentioning

confidence: 53%

Serum C-reactive protein levels in pre-dialysis chronic kidney disease patients in southern Nigeria

Adejumo¹,

Okaka²,

Okwuonu³

et al. 2016

Ghana Medical Journal

View full text Add to dashboard Cite

SUMMARYBackground: Cardiovascular disease is the major cause of hospitalization and mortality in chronic kidney disease (CKD). C-reactive protein (CRP) is a marker of cardiovascular disease and predictor of mortality in CKD patients. CKD patients with elevated CRP should be identified early with institution of measures to treat cardiovascular risk factors in order to reduce attendant mortality. Aims: Determination of serum CRP levels in CKD patients and associated factors. Methods: This was a case-control study involving 80 consecutive CKD patients and 40 control subjects without CKD. Data obtained from participants included demographics, body mass index (BMI), and aetiology of CKD. Serum CRP levels, albumin, creatinine and lipid profile were determined. Cases and controls were compared. P values <0.05 were taken as significant Results: The mean age of the CKD subjects was 49.09±16.85 years. The median CRP value was significantly higher in the CKD group compared to controls (p=<0.001). Low, average and high cardiovascular event risk according to CRP values were present in 51(63.8%), 13(16.2%) and 16(20%) of the CKD patients respectively. Cardiovascular event risk was significantly higher in CKD subjects (p=<0.001). Serum creatinine, BMI, triglyceride and atherogenic index of plasma correlated positively with CRP. Estimated glomerular filtration rate (eGFR), high density lipoprotein-cholesterol and albumin correlated negatively with CRP. Elevated serum CRP was significantly predicted by low eGFR and high BMI on multivariate analysis. Conclusion: Chronic kidney disease patients have increased cardiovascular event risk. Interventions aimed at reducing weight and treating dyslipidaemia should be instituted early in order to reduce this risk.

show abstract

“…It is well established that HDL-cholesterol concentrations are inversely associated with triglyceride concentrations due to their interrelated metabolic fates. In addition to the role of HDL in promoting cholesterol effl ux, HDL composition and structure are also emerging as being important for this process ( 22 ). In one small study, patients with CHD or CHD risk factors had proinfl ammatory HDL relative to matched controls at baseline, and about one-half continued to have proinfl ammatory HDL after statin therapy despite a profound decrease in plasma lipids.…”

Section: Appendixmentioning

confidence: 99%

Cholesterol absorption and synthesis markers in individuals with and without a CHD event during pravastatin therapy: insights from the PROSPER trial

Matthan

Resteghini

Robertson

et al. 2010

Journal of Lipid Research

View full text Add to dashboard Cite

This article is available online at http://www.jlr.org a CHD event during pravastatin therapy: insights from the PROSPER trial. J. Lipid Res . 2010. 51: 202-209. Supplementary key words lipoproteins • lathosterol • desmosterol • phytosterolsElevated plasma LDL-cholesterol and triglyceride concentrations and low HDL-cholesterol concentrations are well-established risk factors for coronary heart disease (CHD) ( 1, 2 ). Several primary and secondary prevention trials have documented that statin therapy is effi cacious in lowering these lipid risk factors and subsequent CHD events and mortality ( 3-10 ). Nonetheless, CHD events still occur in some treated patients. For instance, in the Scandinavian Simvastatin Survival Study, which evaluated the effect of simvastatin on mortality and morbidity in 4444 CHD patients, simvastatin (20-40 mg/day) lowered LDLcholesterol concentrations by 35% and raised HDLcholesterol concentrations by 8% relative to placebo ( 8 ). These changes were associated with a 42% reduction in the risk of coronary deaths over a 5.4 year median follow-up period. However, there were 431 coronary events and 111 CHD-related deaths in the simvastatin-treated group.Likewise, the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) Trial examined the effects of pravastatin therapy (40 mg/day) in an elderly cohort of Abstract Cholesterol homeostasis, defi ned as the balance between absorption and synthesis, infl uences circulating cholesterol concentrations and subsequent coronary heart disease (CHD) risk. Statin therapy targets the rate-limiting enzyme in cholesterol biosynthesis and is effi cacious in lowering CHD events and mortality. Nonetheless, CHD events still occur in some treated patients. To address differences in outcome during pravastatin therapy (40 mg/day), plasma markers of cholesterol synthesis (desmosterol, lathosterol) and fractional cholesterol absorption (campesterol, sitosterol) were measured, baseline and on treatment, in the Prospective Study of Pravastatin in the Elderly at Risk trial participants with (cases, n = 223) and without (controls, n = 257) a CHD event. Pravastatin therapy decreased plasma LDL-cholesterol and triglycerides and increased HDLcholesterol concentrations to a similar extent in cases and controls. Decreased concentrations of the cholesterol synthesis markers desmosterol ( ؊ 12% and ؊ 11%) and lathosterol ( ؊ 50% and ؊ 56%) and increased concentrations of the cholesterol absorption markers campesterol (48% and 51%) and sitosterol (25% and 26%) were observed on treatment, but the magnitude of change was similar between cases and controls. These data suggest that decreases in cholesterol synthesis in response to pravastatin treatment were accompanied by modest compensatory increases in fractional cholesterol absorption. The magnitude of these alterations were similar between cases and controls and do not explain differences in outcomes with pravastatin treatment.-N. R. Matthan, N.

show abstract

High-density lipoprotein: Antioxidant and anti-inflammatory properties

Cited by 86 publications

References 26 publications

Ambient ultrafine particles alter lipid metabolism and HDL anti-oxidant capacity in LDLR-null mice

Ambient ultrafine particles alter lipid metabolism and HDL anti-oxidant capacity in LDLR-null mice

Serum C-reactive protein levels in pre-dialysis chronic kidney disease patients in southern Nigeria

Cholesterol absorption and synthesis markers in individuals with and without a CHD event during pravastatin therapy: insights from the PROSPER trial

Contact Info

Product

Resources

About